A new covid variant called XFG, nicknamed “Stratus,” has emerged as a significant strain spreading across the United States and globally in 2026. The variant was first detected in Southeast Asia in early 2025 and has steadily increased its presence, though it currently poses a low public health risk according to the World Health Organization.
XFG is a combination of two earlier covid strains and shows enhanced ability to evade immune responses, though existing vaccines remain effective against severe disease. This variant has climbed from nearly zero percent of US cases in early 2025 to becoming one of the dominant strains by mid-year.
Understanding what makes this variant different, how it spreads, and what symptoms to watch for helps us protect ourselves and our communities. The good news: XFG doesn’t appear to cause more severe illness than other recent variants, and our current testing methods can still detect it.
What Is the New Covid Variant?
The XFG variant, commonly called Stratus, represents the latest dominant form of SARS-CoV-2 circulating in the United States as of early 2026. This Omicron descendant emerged from Southeast Asia and now accounts for the vast majority of COVID-19 cases across the country.
How the Stratus (XFG) Variant Emerged
XFG first appeared in Southeast Asia in January 2025. By spring of that year, it was detected in the United States.
The variant reached American shores through international travel. As people resumed normal activities and travel patterns, XFG found opportunities to spread.
By July 2025, there was a clear uptick in cases. Summer travel, return-to-school schedules, and relatively low vaccination rates created ideal conditions for transmission.
By September 2025, XFG accounted for 79% of U.S. COVID cases, far outpacing the NB.1.8.1 Nimbus variant that had been circulating earlier.
Understanding Variant Naming: Pango Lineages Explained
Pango lineages classify SARS-CoV-2 variants systematically, tracking the virus’s evolutionary branches as it mutates over time. The XFG designation provides specific information about the variant’s genetic ancestry.
Each letter and number combination maps the virus’s place in the broader family tree of SARS-CoV-2. Scientists assign these technical names based on genetic sequencing data.
Nicknames like “Stratus” make variants easier to discuss publicly. The World Health Organization and public health agencies use both systems—Pango lineages for scientific precision and common names for public communication.
What Makes XFG Different from Other Variants
XFG is a hybrid variant formed from two existing Omicron subvariants: LF.7 and LP 8.1.2. This genetic mixing gives it distinct characteristics.
Key differences include stronger cellular binding, allowing XFG to attach more tightly to human cells and potentially increasing transmissibility. The variant can better avoid antibodies from prior infections or vaccinations.
Sore throat appears as the predominant symptom, though overall symptoms remain similar to other variants. Hospitalization rates haven’t surged dramatically, and the current 2025-2026 vaccine targets LP.8.1, a closely related strain, providing protection against severe outcomes from XFG infection.
How the New Covid Variant Is Spreading
The XFG variant now accounts for 85% of COVID-19 cases in the United States, with the strongest concentration in the Northeast and Western regions. Transmission patterns reflect both viral characteristics and regional population behaviors.
Geographical Spread and Hotspots
The Centers for Disease Control and Prevention tracks viral activity through wastewater surveillance, catching infections before people even know they’re sick. Connecticut leads the nation with “very high” viral activity levels, followed by Massachusetts, Rhode Island, and New York.
Out West, Nevada and Utah both register “very high” activity levels. Most Western states show “high” levels of wastewater detection, indicating sustained community transmission.
Vermont stands out with “low” activity, while Michigan and Missouri record “very low” levels, showing that transmission patterns vary significantly across the country.
Global cases jumped by 30,000 over recent weeks, according to the World Health Organization’s COVID dashboard. Actual infection numbers likely exceed reported figures due to decreased testing worldwide.
Factors Influencing Variant Transmission
The XFG variant emerged from the Omicron lineage. It remained relatively quiet through spring before surging during late summer months.
The World Health Organization designated Stratus as a “variant under monitoring.” This means health officials track its spread and characteristics without declaring it a major threat.
We’re seeing a typical late summer COVID surge, mirroring previous years when respiratory viruses gain momentum as people gather indoors more frequently. The NB.1.8.1 variant (called “Nimbus”) holds about 7% of current cases.
Both variants spread through the same respiratory droplet transmission that characterized earlier COVID-19 strains. The CDC says infected individuals remain most contagious during the first five days after symptom onset.
Key Symptoms of the New Covid Variant
The Stratus variant presents with a familiar set of symptoms that closely mirror earlier Omicron strains. Upper respiratory issues dominate the clinical picture, while systemic symptoms like fatigue and body aches remain common.
Upper Respiratory Symptoms to Watch
Sore throat stands out as the most frequently reported symptom with the current Stratus variant. Some patients describe this as particularly severe, using terms like “razor blade throat” or experiencing significant hoarseness.
Cough remains a hallmark symptom, often appearing dry at first before potentially developing into a productive cough. Widespread reports of congestion and runny nose make it difficult to distinguish Covid from seasonal allergies or common colds.
Shortness of breath continues to affect some individuals, particularly those with underlying respiratory conditions. Loss of taste or smell, while less common than in earlier variants, still occurs in some cases.
Testing remains the only reliable way to confirm Covid-19 when these respiratory symptoms appear.
Common Systemic Symptoms
Fever or chills frequently accompany upper respiratory symptoms, though not everyone develops an elevated temperature. When fever does occur, it tends to be mild to moderate.
Fatigue hits many patients hard, often lasting beyond other symptoms. Headache appears regularly, ranging from mild pressure to more intense pain.
Muscle aches affect a significant portion of those infected, creating that familiar “flu-like” feeling throughout the body. These aches can vary in intensity and typically improve as the infection resolves.
Unusual Symptoms Linked to New Strains
While the Stratus variant doesn’t seem to cause entirely new symptoms, some less common presentations are being tracked. Nausea or vomiting affects a subset of patients, particularly in the early stages of infection.
Gastrointestinal issues like diarrhea occur occasionally, though these remain less frequent than respiratory symptoms. Confusion and cognitive difficulties have been reported in some cases, especially among older adults or those with severe infections.
The severity and combination of symptoms varies considerably from person to person. Vaccination status, age, and overall health all influence how symptoms manifest and how long they persist.
How Contagious Is the New Covid Variant?
The latest COVID-19 variants circulating in 2026 show increased transmissibility compared to earlier strains. Variants like XFG (Stratus) and NB.1.8.1 spread more rapidly due to specific genetic mutations that enhance their ability to bind to human cells.
Transmissibility Compared to Older Strains
Current variants are more contagious than their predecessors. The XFG variant demonstrates higher transmissibility than previous Omicron variants.
NB.1.8.1, another variant under monitoring, spreads even faster due to its tighter binding to human cells. Health officials in Hong Kong confirm that NB.1.8.1 doesn’t cause more severe illness than previous strains; the challenge lies in transmission speed.
The CDC continues tracking these Omicron variants as they replace earlier COVID-19 strains. SARS-CoV-2 constantly accumulates mutations, and variants with transmission advantages typically outcompete older versions.
Current case surges in China and detections at US airports in California, Washington, Virginia, and New York signal broader circulation, though reported US cases remain under 20 as of recent data.
Contagion Duration and Isolation Guidelines
Follow the same protocols as for influenza or other respiratory viruses when dealing with COVID-19 variants. The virus remains contagious during active symptom periods, which typically include fever, cough, sore throat, and fatigue.
Current guidance from health authorities suggests isolation when symptomatic. Essential precautions include:
- Wash hands thoroughly and frequently
- Cover your mouth when coughing or sneezing
- Wear N95 masks in public spaces during active transmission periods
- Stay home when experiencing symptoms
Existing COVID-19 vaccines still provide protection against these variants, according to the World Health Organization. Vaccination is strongly encouraged, though recent policy changes have limited booster recommendations primarily to older adults and individuals with certain health conditions.
Testing for the New Covid Variant
Current at-home and laboratory tests remain effective at detecting the XFG variant. Testing strategies have evolved to balance public health needs with practical considerations for individuals and workplaces.
How Well Do Current Tests Detect XFG?
At-home COVID-19 tests work well for detecting the XFG variant. The antigen these tests identify has stayed stable even as SARS-CoV-2 variants evolved.
The tests detect viral proteins called antigens, which haven’t changed significantly in XFG compared to earlier variants. Research shows antigen tests identify about 90% of COVID-19 cases when people have symptoms, though this drops to around 50% for asymptomatic infections.
Key points about test accuracy:
- Results appear within 15 minutes
- False positives are rare
- False negatives are more common, especially early in infection
- The CDC recommends repeat testing 48 hours after a negative result if you have symptoms
Combination flu and COVID-19 tests have also received FDA authorization. These dual tests can identify both viruses from a single nasal swab, which is useful since symptoms overlap considerably.
Testing Guidelines for Individuals and Businesses
Test when respiratory symptoms appear—cough, fever, runny nose, or the signature sore throat associated with XFG. Test before gathering with high-risk individuals, including older adults or immunocompromised people.
For businesses, testing strategies depend on your specific circumstances. Healthcare facilities maintain different protocols than office environments.
Consider testing employees who develop any respiratory symptoms at work, report known exposure to COVID-19, or return after sick leave with lingering symptoms. Free government test kits remain available through the U.S. Department of Health & Human Services website, with four tests per household per order.
Some insurance plans still cover additional at-home tests. Check expiration dates before testing; the FDA has extended dates for many test kits, so verify your specific brand on the FDA website before discarding expired-looking tests.
Risk Factors: Who Should Be Most Vigilant?
While new COVID variants like XFG Stratus can affect anyone, certain groups face higher risks of severe illness and complications. Understanding your individual risk profile helps determine how aggressively you should approach protective measures.
Immunocompromised and High-Risk Groups
People with weakened immune systems remain particularly vulnerable to new COVID variants. This includes individuals undergoing cancer treatment, organ transplant recipients, and those taking immunosuppressive medications.
Heightened risk is seen among people living with HIV, those receiving chemotherapy, and individuals with autoimmune conditions requiring immune-suppressing drugs. These groups often mount weaker responses to vaccination, making them more susceptible to breakthrough infections.
High-risk groups should consider consulting their clinicians about additional vaccine doses, discussing Paxlovid prescriptions for immediate use if infected, maintaining stricter masking protocols in crowded settings, and avoiding high-transmission environments when possible.
The CDC specifically recommends antiviral medications like Paxlovid for immunocompromised individuals who test positive. Vaccination may also help prevent long COVID, a condition that can develop even after mild infections and cause persistent symptoms.
Age and Chronic Health Conditions
Adults aged 65 and older face elevated risks from new variants, regardless of general health. Their immune systems naturally decline with age, reducing infection-fighting ability.
Chronic conditions amplify COVID-19 severity. Diabetes, heart disease, high blood pressure, asthma, and obesity all increase the likelihood of hospitalization and complications.
Pregnant individuals are also at higher risk.
Key conditions that increase vulnerability:
- Cardiovascular disease: Compromises the body’s stress response during infection.
- Diabetes: Impairs immune function and wound healing.
- Respiratory conditions: Heighten risk of dangerous breathing complications.
- Obesity: Linked to inflammation and reduced lung capacity.
Anyone over 12 with these conditions qualifies for Paxlovid prescriptions. These groups should stay current with vaccinations and discuss personalized protection with healthcare providers.
The Current Vaccine Landscape
The 2025-26 COVID vaccines target the LP.8.1 strain and provide measurable protection against severe disease from circulating variants. Most new variants remain part of the Omicron family, so existing vaccines still help prevent hospitalization and death.
Do Vaccines Protect Against the New Variant?
Current vaccines protect against new variants. The 2025-26 formulation targets LP.8.1, which is genetically similar to early 2026 variants.
Protection against severe outcomes remains consistent across age groups, though effectiveness varies with immune status. New variants like NB.1.8.1 and XFG Stratus evolved from strains already included in vaccine development.
Key protection levels include:
- Strong defense against hospitalization
- Reduced risk of severe disease requiring emergency care
- Lower transmission rates among vaccinated individuals
The CDC confirms vaccination is the most reliable defense against serious illness. Vaccinated people typically experience milder infections, even with breakthrough cases.
Vaccine Updates and Effectiveness
The FDA approved the current vaccine after analyzing which variants were most widespread. This formula differs from the 2024-25 version, which targeted KP.2 strains.
Moderna and Pfizer produce mRNA vaccines that start generating antibodies within two to three days. Peak effectiveness arrives after one to two weeks.
Novavax offers a protein-based option using JN.1 as its parent strain.
The World Health Organization continues monitoring variant evolution for future updates. While vaccine effectiveness against infection decreases over time, protection against severe outcomes remains more durable.
Guidelines for Boosters
The CDC recommends updated COVID-19 vaccines for everyone ages 6 months and older, regardless of previous vaccination status.
Special recommendations for high-risk groups:
- Adults 65 and older should receive a second dose six months after their initial 2025-26 vaccination.
- Immunocompromised individuals also qualify for additional doses at the six-month mark.
Fall and winter are ideal for vaccination, as viral transmission increases when people gather indoors. Getting vaccinated before holiday gatherings offers optimal protection.
COVID and flu vaccines can be received simultaneously in separate arms.
Major Covid Variants Making Headlines
XFG (Stratus) currently dominates, accounting for 79-85% of US cases. NB.1.8.1 (Nimbus) holds a smaller share at about 7%.
These variants stem from recombination events involving parent lineages F.7 and LP.8.1.2.
XFG Versus NB.1.8.1 and KP.3
XFG, or Stratus, is the dominant strain. Emerging from Southeast Asia in January 2025, it reached the US by spring. By early September, it made up 79% of cases, climbing to 85% by month’s end.
Stratus is a recombinant variant, combining genetic material from Omicron subvariants LF.7 and LP.8.1.2. This gives it enhanced binding capability to human cells.
The predominant symptom is sore throat, with fever, fatigue, cough, and congestion also common.
NB.1.8.1, or Nimbus, trails at about 7% of cases. Nimbus is notable for its distinctive symptom: a sharp, stabbing throat pain when swallowing.
Though spreading internationally, Nimbus remains less common in the US.
The current vaccine targets LP.8.1, closely related to the main circulating strains. No dramatic hospitalization increases have been seen with either variant.
Other Noteworthy Variants: F.7 and LP.8.1.2
F.7 and LP.8.1.2 are parent lineages, contributing genetic material to create XFG through recombination.
LP.8.1.2 was the second most prominent US strain before XFG’s rise. The 2025-2026 vaccine specifically targets LP.8.1, offering protection against descendant variants with similar genetics.
F.7 is the other half of XFG’s genetic heritage. Combined with LP.8.1.2, these parent strains produced a hybrid with improved transmissibility.
Understanding these parent lineages helps anticipate future variants. Recombination between circulating strains will likely keep producing new, unpredictable variants.
How Covid Variants Are Monitored
Health agencies track new SARS-CoV-2 variants through genetic sequencing and model-based projections. The CDC and WHO coordinate global surveillance to identify variants that could impact public health.
Genomic Surveillance: How It Works
Genomic surveillance sequences the genetic material of SARS-CoV-2 samples from positive COVID-19 tests. Some specimens are sent to labs where scientists decode the virus’s complete genetic sequence.
The process involves:
- Sample collection from testing facilities
- Specimen preparation
- Laboratory sequencing and analysis
- Upload to public databases like GenBank
The CDC receives specimens through the National SARS-CoV-2 Strain Surveillance program. Other labs contribute sequencing data to create a comprehensive picture of circulating variants.
Scientists compare genetic sequences to identify mutations and classify variants.
The CDC uses two calculation methods for variant proportions. Empiric estimates reflect observed genetic sequences but lag behind current conditions. Nowcast estimates use mathematical models to project recent variant proportions before complete data is available.
These projections can show wider uncertainty for emerging, fast-growing variants.
Roles of CDC and WHO in Monitoring
The CDC monitors variant proportions across the US and updates its data every Tuesday. The National SARS-CoV-2 Strain Surveillance program coordinates with state and local labs.
The WHO takes a global approach, classifying variants as variants of concern (VOC), variants of interest (VOI), or variants under monitoring (VUM). This helps countries prioritize research and public health responses.
Both organizations share genomic data internationally. The WHO assigns Greek letter labels to significant variants for public communication. Scientists use the Pango system for technical classification.
The CDC focuses on variants above 1% prevalence in the US, grouping rarer lineages with parent variants for clearer reporting.
Protecting Yourself and Your Workplace
Vaccination remains the cornerstone of protection against emerging COVID-19 variants. Practical measures like improved ventilation and clear sick policies help businesses maintain healthy operations.
Personal Prevention Strategies
The updated 2025-2026 COVID-19 vaccine targets strain LP.8.1, closely related to current variants like XFG (Stratus). Vaccines may not prevent mild symptoms, but they dramatically reduce the risk of severe illness and long COVID.
Core protective measures include:
- Hand hygiene: Frequent handwashing with soap for at least 20 seconds
- Testing: When symptoms like sore throat, fever, or fatigue appear
- Masking: N95 respirators offer the strongest protection in crowded indoor spaces
- Distancing: Staying home when sick prevents transmission
The CDC emphasizes that layered approaches work best. Previous infections don’t guarantee immunity against new variants. Testing allows early access to treatments that reduce severe outcomes.
If recovering from COVID-19, wearing an N95 mask protects vulnerable people during the infectious period.
Business Best Practices During Variant Surges
Clear policies should encourage sick employees to stay home without fear of lost income. Respiratory viruses now peak both in winter and during warm months, so year-round preparedness is key.
Essential workplace strategies:
| Strategy | Implementation |
|---|---|
| Ventilation | Upgrade HVAC filters, open windows when possible |
| Testing availability | Provide free rapid tests for symptomatic staff |
| Flexible work | Enable remote work during local surges |
| Vaccination clinics | Partner with providers for on-site vaccine access |
Masks should be welcomed but not required. Some employees have underlying conditions like diabetes or heart disease that increase risk.
Visible hand sanitizer reinforces good hygiene. During local surges, temporarily increase cleaning of high-touch surfaces while maintaining baseline protections year-round.
Potential Long-Term Effects of Covid Variants
The virus continues to evolve, and each variant raises questions about lasting health impacts. Research shows different variants can affect how long symptoms persist after infection.
Long Covid: What We Know
Long COVID affects a substantial portion of people who contract SARS-CoV-2. Studies of hospitalized patients found that 35.2% reported persistent symptoms one month after infection, though this number decreases over time.
The Omicron variant initially caused more intense symptoms in the first month compared to earlier variants. By 12 months, symptom levels were similar to those infected with pre-Omicron strains.
Specific viral lineages matter. Certain Delta lineages (AY.126 and AY.43) and Omicron sublineages (BA.1.17, BA.2.56, BA.5.1) consistently correlated with more severe long-term symptoms.
Common persistent symptoms include:
- Fatigue and general weakness
- Respiratory difficulties
- Cognitive issues
- Gastrointestinal problems
Key Steps for Recovery and Support
A structured approach is crucial for managing post-COVID symptoms. Vaccination status provides significant protection against severe long COVID outcomes, even after infection.
Healthcare providers should schedule multiple follow-up visits. Symptom intensity often shifts over time, with many patients improving between the first and sixth months after infection.
Recovery priorities should focus on:
- Regular symptom tracking across multiple health domains
- Maintaining up-to-date vaccination status
Early intervention is recommended when symptoms worsen. Multidisciplinary medical support is essential for complex cases.
Anti-SARS-CoV-2 antibody levels play a role in long-term outcomes. Patients with higher antibody levels from vaccination generally experience less severe persistent symptoms than those relying solely on natural immunity.